-
Australia has developed a new method of purification of cancer CAR-T immunotherapy preparations
Time of Update: 2020-11-05
OCT 28 (Xinhua) -- Researchers at the University of South Australia, in collaboration with a biotherm treatment company, have developed a new method based on microflower technology to purification of cancer CAR-T immunotherapy preparations that can reduce treatment costs and side effects, the University of South Australia said in a press release.
-
1.5 billion blood lipid-lowering drugs! China Resources Double Crane has been evaluated
Time of Update: 2020-11-04
2019, sales of pivastatin at public medical institutions in China exceeded 1.5 billion yuan, up 47.50 percent year-on-year, according to the company's internal data.
pivastatin calcium tablets manufacturers have Japan Xinghe, Xinlitai, Qidu Pharmaceuticals, China Resources Shuanghe, Changao Pharmaceuticals, Wanbang Pharmaceuticals and other 5; pyvastatin for the third batch of harvested varieties.
-
Ministry of Science and Technology: 4 new crown vaccines entered Clinical Phase III 60,000 people were vaccinated without serious adverse reactions.
Time of Update: 2020-10-28
Pharma Network October 21 - The Ministry of Science and Technology, Deputy Director of the Department of Social Development Science and Technology Tian Baoguo said on the 20th, four into phase III clinical trial stage of the new crown vaccine, overall progress is progressing smoothly, so far a total of about 60,000 subjects have been vaccinated, no serious adverse reactions reported.
-
State Council Prevention and Control Mechanism: The new coronavirus mutation has not had a real impact on vaccine research and development.
Time of Update: 2020-10-28
comparative analysis of more than 80,000 high-quality viral genome sequences showed that the virus had little variation, was within the normal range of mutation accumulation, and had no substantial impact on vaccine development.
-
Guangdong side of the pharmaceutical wet detox particles won the first overseas drug registration approval.
Time of Update: 2020-10-27
Pharma Network October 22 - Recently, Guangdong One Party Pharmaceutical Co., Ltd. (hereinafter referred to as One Party Pharmaceutical) received the United Arab Emirates (hereinafter referred to as t
-
Qilu University's first injection supplement application has been evaluated and 41 products lead the industry
Time of Update: 2020-10-27
Qilu Pharmaceutical's consistent evaluation results in the industry in a leading position, Milnet data show that up to now the company has reviewed or reviewed the number of products up to 41, of which according to the new classification registered approved and evaluated 25 products (including 3 injections: oxalibhin injection, injection with yew alcohol (albumin binding type), injection with bivalditin), consistent evaluation of the supplementary application approved products have 16 (including 1 injection: injection of paroxeb sodium).
-
Studies say infection with the new coronavirus may not necessarily translate into complete immunity.
Time of Update: 2020-10-19
MEDICINE NETWORK, Oct. 14 (Xinhua) -- Analysis of the first case of new coronary secondary infection in the United States shows that infection with the virus may not translate into complete immunity, U.S. researchers said in a study published Tuesday.
-
National "major new drug creation" results Dabohua was approved for listing.
Time of Update: 2020-10-19
Zhou Hui, vice president of biomedical science and strategic oncology at Xinda, said that as a result of the country's "major new drug creation", Dabohua's listing will effectively reduce the cost of drug use for relevant patients, improve access to clinical drugs, and better meet the needs of the people for high-quality biological drugs.
-
Merohua again to meet the opponent of the second domestic lytoxi single anti-listing.
Time of Update: 2020-10-19
public information shows that the primary drug for lysiocyte monoantigene is Merohua, the first monoclonal antibody approved by the FDA to treat cancer by Roche Genentech, since its launch in 1997 Merohua has been approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, hemanitis granuloma, multi-angiotis under the microscope, moderate to severe adult herpes and other adaptations.
-
Top 5 is acquired by Healthcare Technologies since 2020.
Time of Update: 2020-10-17
4Invitae's $1.4 billion acquisition of Archer DX on June 22, Invitae, a leader in genetic disease testing, announced that it will acquire ArcherDx, a cancer genetic testing company, to include the latter in the income sacs of gene testing and liquid biopsy technology and related products for tumor efficacy prediction and monitoring.
-
With 1.9 billion injections, this Jiangsu pharmaceutical company will be the first to be evaluated.
Time of Update: 2020-10-10
/long-chain fat emulsion is a fast and short-acting intravenous anesthetic with terminal sales of more than 1.9 billion yuan in public medical institutions in China in 2019.
-
More than 10 billion U.S. dollars of lysovirus market The latest developments in The country at a glance.
Time of Update: 2020-10-10
Wuhan Binzhou Bin association biotech recombinant person GM-CSF lysoma type II herpes simplex virus (OH2) injection (Vero cells) combined PD-1/L1 treatment can not be surgically removed, standard treatment failure of advanced solid tumors (such as breast cancer, melanoma, head and neck cancer, soft tissue sarcoma, liver cancer or liver metastasis tumor, etc.) treatment.
-
Compete with Chia Tai Tianqing and Yangzijiang for another Chengdu pharmaceutical company to disrupt antidepressants
Time of Update: 2020-10-02
Prior to this, the product Yangzijiang to imitation 3 categories, Zhengda Tianqing Pharmaceutical Group and Chengdu Beit Pharmaceuticals to copy 4 categories of submitted applications for listing, in the review and approval (in the drug review center).
-
There are new discoveries about metformin.
Time of Update: 2020-10-02
the risk of lung cancer death was significantly reduced by 13% and 23%, respectively, in people who had taken aspirin or statins cumulatively over a two-year period of 547.5 days.
-
Domestic anti-cancer new drugs approved for listing increased by 125% YoY, forcing MNC, Hengrui, Baiji hit out head-on!
Time of Update: 2020-10-02
Among them, the local new sharp represented by Baiji Shenzhou with the approval of two new drugs, and Heng Rui Qiping, and Hengrui with the expansion of 2 PD-1 new adaptive disorders, directly forced the K medicine of Merca East, in this innovation battle, the local pharmaceutical companies are ferociously surrounding MNC.
-
900 million antibacterial drugs will welcome the third review! Hebei pharmaceutical companies "rush to fight" Baiyunshan, Sinopharm
Time of Update: 2020-10-02
Pharmaceutical Network September 23rd, September 22nd, CDE official website shows that North China Pharmaceuticals Hebei Huamin Pharmaceuticals' cephalosporine particles to copy 3 categories of filing
-
Two needles 600 yuan, the domestic new crown vaccine pricing out, the global vaccine price in China ranked no.
Time of Update: 2020-09-30
china's current demand for vaccines, the solution to the vaccine price problem in addition to the national shot, can also be "wait." now give vaccine companies more flexibility to commercially price vaccines at reasonable prices to more urgently needed international markets, while some of the country's most in-need people can inject them at their own expense.
-
60 new drugs approved clinically! Domestic class 1 new drugs exploded.
Time of Update: 2020-09-30
Reding Pharmaceuticals' toluene sulfonate Nirapali capsules, Roche's Beva bead monoantigen injections were approved for new adaptations, Cinda Bio's Lytoxi monoantigen injections, Pfizer's chlorobenzene softgels, merck Sante's hydrochloric acid metformin tablet registration status changed to "in-approval." (9.12-9.25) New drug listing application review status update Roche's Beva pearl monoantigen injection (avivitin) was approved for treatment in adult relapsed glioblastoma (GBM) patients.
-
A Chinese research team has developed a malignant cancer inhibitor.
Time of Update: 2020-09-30
recently, Liu Qingsong, a researcher at the Institute of Health and Medical Technology of the Hefei Research Institute of the Chinese Academy of Sciences, and Liu Jing, a researcher in pharmacy, developed a new generation of highly selective, highly active BTK kinase inhibitor CHMFL-BTK-85 for B-cell non-Hodgkin's lymphoma.
-
200 million levels of Japanese cardiovascular drugs without a copy? The Shijiazhuang pharmaceutical company is hitting again.
Time of Update: 2020-09-29
3: Clinical situation of hydrochloric acid arolol tablets Source: Minet China Drug Clinical Trials PublicIty Library original research listed in China for more than 20 years, domestic generic drugs are actually a blank?
